Vasomune Therapeutics is a biotechnology company, developing therapies for blood vessel diseases - vascular dysfunction and destabilization.
Vasomune has raised $6.4M in total funding. The most recent round was Grant. The last funding was announced in November 2021.
Vasomune's investors include U.S. Department of War, Genome Canada, National Research Council of Canada Industrial Research Assistance Program, Toronto Innovation Acceleration Partners, Sunnybrook Research Institute.
Vasomune is headquartered in Toronto, Canada.
Vasomune Therapeutics is a biotechnology company, developing therapies for blood vessel diseases - vascular dysfunction and destabilization.
Vasomune is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vasomune — Funding & Investors." VCBacked, November 8, 2021, https://www.vcbacked.co/company/vasomune. Accessed August 14, 2026.
VCBacked. (2021). Vasomune — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vasomune
{{cite web |title=Vasomune — Funding & Investors |url=https://www.vcbacked.co/company/vasomune |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated